Fernando Muñoz Núñez

P1065 Rapid onset of action of ustekinumab in patients with moderate to severe Ulcerative Colitis (RAUCU Study)

Iria Bastón‐Rey, Marta Alvarado, B. Suarez, I. Latras-Cortés et autres

Abstract Background Real-world data on the speed of onset of ustekinumab (UST) in patients with ulcerative colitis (UC) are limited. Current information regarding early response in these patients comes from the UNIFI trial. The primary outcome of this study was to evaluate …

es, us (code pays fourni par la source)

P0388 Can intestinal ultrasound guide us in the treatment of inflammatory bowel disease?

Vanessa Prieto Vicente, Alejandra Fernández Pordomingo, Raquel Domínguez Gómez, Rocío Gómez Hidalgo et autres

Abstract Background Intestinal Ultrasonography (IUS) is a useful method for monitoring inflammatory bowel disease. The role of Shear Wave Elastography (SWE) and the relationship with other parameters indicating activity are not yet well understood. Methods The aim was to describe the ultrasound …

es (code pays fourni par la source)

Efficacy of Beclomethasone Dipropionate in Lowering Fecal Calprotectin Levels in Patients with Ulcerative Colitis in Clinical Remission and at Risk of Relapse: The Becalcu Randomized, Controlled Trial

Daniel Ginard, Manuel Barreiro‐de Acosta, Pilar Nos, Irene Moraleja et autres

INTRODUCTION: Identifying novel treatment strategies for patients with ulcerative colitis (UC) and at risk of relapse is critical. The objective of this study was to assess the efficacy of beclomethasone dipropionate (BDP) in lowering fecal calprotectin (FC) levels in UC patients in …

es (code pays fourni par la source)

Therapeutic drug monitoring in inflammatory bowel diseases. Position statement of the Spanish Working Group on Crohn’s Disease and Ulcerative Colitis

Francisco Rodríguez‐Moranta, Federico Argüelles‐Arias, Joaquín Hinojosa del Val, Marisa Iborra Colomino et autres

The treatment of inflammatory bowel disease has undergone a significant transformation following the introduction of biologic drugs. Thanks to these drugs, treatment goals have evolved from clinical response and remission to more ambitious objectives, such as endoscopic or radiologic remission. However, even …

es (code pays fourni par la source)

Monitorización terapéutica de los fármacos biológicos en la enfermedad inflamatoria intestinal. Documento de Posicionamiento del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU)

Francisco Rodríguez‐Moranta, Federico Argüelles‐Arias, Joaquín Hinojosa del Val, Marisa Iborra Colomino et autres

El tratamiento de la enfermedad inflamatoria intestinal ha sufrido una gran transformación tras la introducción de los fármacos biológicos. Gracias a ellos, los objetivos del tratamiento han evolucionado desde la respuesta y remisión clínica a objetivos más ambiciosos, como la remisión endoscópica …

es (code pays fourni par la source)

The Risk of Developing Disabling Crohn’s Disease: Validation of a Clinical Prediction Rule to Improve Treatment Decision Making

Guillermo Bastida, Olga Merino Ochoa, Manuel Barreiro‐de Acosta, Yamile Zabana et autres

BACKGROUND: Crohn's disease (CD) is characterized by the development of complications over the course of the disease. It is crucial to identify predictive factors of disabling disease, in order to target patients for early intervention. We evaluated risk factors of disabling CD …

es, no (code pays fourni par la source)

ABP 501 (adalimumab-atto) in the treatment of inflammatory bowel disease: an example of evidence-based extrapolation

Fernando Muñoz Núñez, Carlos Taxonera, J. T. Marron

We report the available evidence demonstrating the biosimilarity of ABP 501 (AMGEVITA®, adalimumab-atto) to its reference product (RP) (Humira®, adalimumab), and the rationale for the extrapolation of the results obtained with the RP in inflammatory bowel disease (IBD) to ABP 501. Based …

es, us (code pays fourni par la source)

P223 Efficacy and safety of tacrolimus in Crohn’s disease: a nationwide, multi-centric study from GETECCU

Iago Rodríguez–Lago, Jesús Castro‐Poceiro, Agnes Fernandez-Clotet, Francisco Mesonero et autres

Crohn's disease (CD) is chronic inflammatory disease of the gastrointestinal tract. Tacrolimus (TCR) is a calcineurin inhibitor drug commonly used for prophylaxis of rejection in renal and liver transplantation. There is some evidence on the short- and medium-term efficacy and safety of …

es (code pays fourni par la source)

DOP44 Efficacy and safety of tacrolimus in ulcerative colitis: a nationwide, multi-centre study from GETECCU

Iago Rodríguez–Lago, Jesús Castro‐Poceiro, Agnes Fernandez-Clotet, Francisco Mesonero et autres

Ulcerative colitis (UC) is a chronic disorder of the gut. Tacrolimus (TCR) is a calcineurin inhibitor drug commonly used for prophylaxis of rejection in renal and liver transplantation. There is some evidence supporting the short- and medium-term efficacy and safety of tacrolimus …

es (code pays fourni par la source)

Uso del ustekinumab en la enfermedad inflamatoria intestinal: a propósito de tres casos

Cristina Pisabarros Blanco, Begoña Álvarez-Cuenllas, Maria Garcia Alvarado, Luis Manuel Vaquero et autres

es (code pays fourni par la source)

[Multiple hepatic focal nodular hyperplasia: its presentation in childhood and atypical evolution].

Fernando Muñoz Núñez, A Herrera Abián, J. Díez, María Gundín et autres

Multiple focal nodular hyperplasia is an uncommon benign liver tumor although its incidence has been increasing in the last few years. A case of focal nodular hyperplasia in a young woman is described, which was discovered in infancy and which presented two …

es (code pays fourni par la source)